Truist Securities Maintains Hold on Inari Medical, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Inari Medical (NASDAQ:NARI) while raising the price target from $47 to $60.
July 16, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Inari Medical and raised the price target from $47 to $60, indicating a positive outlook on the stock's potential.
The raised price target from $47 to $60 by Truist Securities suggests a positive outlook on Inari Medical's future performance. Although the Hold rating remains unchanged, the increased price target indicates that the analyst sees potential for the stock to appreciate in value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100